Related Experiment Video

Updated: Feb 19, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

A First Report on [18F]FPRGD2 PET/CT Imaging in Multiple Myeloma

Nadia Withofs1, François Cousin1, Bernard De Prijck2

  • 1CHU of Liege, Nuclear Medicine and Oncological Imaging Division, Medical Physics Department, Liege, Belgium.

Contrast Media & Molecular Imaging
|November 4, 2017
PubMed

Insights

This study found [18F]FPRGD2 PET/CT detected fewer multiple myeloma lesions compared to low-dose CT or combined [18F]NaF/[18F]FDG PET/CT. Its utility may be limited in advanced disease detection.

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiology

Background:

  • Multiple myeloma (MM) diagnosis and staging rely on accurate lesion detection.
  • Novel imaging agents are needed to improve the detection and characterization of MM bone lesions.

Purpose of the Study:

  • To evaluate the feasibility of [18F]FPRGD2 PET/CT for imaging multiple myeloma.
  • To compare the detection rate of [18F]FPRGD2 PET/CT with low-dose CT and combined [18F]NaF/[18F]FDG PET/CT in MM patients.

Main Methods:

  • Observational study involving four MM patients (2 newly diagnosed, 2 relapsed).
  • Whole-body PET/CT imaging after [18F]FPRGD2 injection.
  • Comparison of [18F]FPRGD2 PET/CT findings with low-dose CT and existing [18F]NaF/[18F]FDG PET/CT data.

Main Results:

  • A total of 81 focal lesions (FLs) were identified across all imaging modalities.
  • [18F]FPRGD2 PET/CT detected fewer FLs (54%) compared to low-dose CT (98%) and [18F]NaF/[18F]FDG PET/CT (70%).
  • All lesions detected by [18F]FPRGD2 PET/CT showed underlying bone destruction or fracture and were also visible on low-dose CT.

Conclusions:

  • [18F]FPRGD2 PET/CT may have limited utility for detecting multiple myeloma lesions, particularly in advanced disease.
  • Low-dose CT alone detected a higher proportion of lesions than [18F]FPRGD2 PET/CT.
  • Further research is needed to determine the specific role of [18F]FPRGD2 in MM imaging.

More Related Videos

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases11:03

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Published on: May 29, 2017

10.5K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.6K

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
7.8K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
630